Home › Research › Biomarkers
Detection of Alzheimer Neuropathology in Alzheimer and Non-Alzheimer Clinical Syndromes With Blood-Based Biomarkers
VandeVrede L, Cho H, Sanderson-Cimino M, Wekselman F, Cobigo Y, Gorno-Tempini ML, Heuer HW, Kramer JH et al.. JAMA neurology, 2025-02-10
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Importance Blood-based biomarkers for Alzheimer disease (AD) are clinically available, but their value is not well understood in syndromes typically associated with frontotemporal lobar degeneration syndromes (FTLD). Objective To investigate the clinical importance and detectability of AD in FTLD-related neurodegenerative syndromes using 3 plasma biomarkers, phosphorylated tau 217 (p-tau217), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP). Design, setting, and participants This clinicopathological study took place at the University of California San Francisco Alzheimer Disease Research Center from August 2008 to July 2022. Autopsied individuals with clinical evaluation and neuropathological examination, diagnosed with clinical syndromes related to AD (n = 125), frontotemporal lobar degeneration (FTLD; n = 198), or cognitively unimpaired (CU) at the time of evaluation (n = 16) were included. Exposures AD-related or FTLD-related clinical syndromes or CU. Main outcomes and measures P-tau217, NfL, and GFAP were measured with single-molecule array (SIMOA). AD was defined as intermediate or high AD neuropathological change (ADNC) at autopsy. Clinical biomarker associations were evaluated using linear regressions. Imaging analyses used bayesian linear mixed-effects modeling. Results A total of 349 individuals (191 [55%] male; mean [SD] age at death, 72 [11] years) were included. AD was common in both AD-related syndromes (110/125 [88%]) and FTLD-related syndromes (45/198 [23%]). Neuropathological stage at autopsy was higher in AD-related syndromes (high ADNC: 82/88 [93%] AD vs 13/23 [56%] FTLD), and AD was frequently considered a copathology in FTLD-related syndromes (30/198 [15%]). Plasma p-tau217 concentrations were higher in AD-related syndromes (mean [SD], 0.28 [0.16] pg/mL) than FTLD-related syndromes (mean [SD], 0.10 [0.09] pg/mL) (P Conclusion Clinically relevant AD was prevalent across neurodegenerative syndromes and detectable with plasma p-tau217. Plasma p-tau217 may be a useful tool to investigate the clinical impact of AD copathology in non-AD neurodegenerative syndromes, including the effect of disease-modifying therapies.
What this study adds
Evidence grade: Low
The record lists 125 participants. This clinicopathological study measured three blood biomarkers (p-tau217, NfL, and GFAP) in 349 autopsied individuals, including people with syndromes usually linked to frontotemporal lobar degeneration. It examined whether these blood tests can detect Alzheimer's disease pathology in people whose clinical syndrome is not typical Alzheimer's, but the available summary does not report how well the biomarkers performed.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
VandeVrede, L., Cho, H., Sanderson-Cimino, M., Wekselman, F., Cobigo, Y., Gorno-Tempini, M. L., et al. (2025). Detection of Alzheimer Neuropathology in Alzheimer and Non-Alzheimer Clinical Syndromes With Blood-Based Biomarkers. JAMA neurology. https://doi.org/10.1001/jamaneurol.2024.5017
Vancouver
VandeVrede L, Cho H, Sanderson-Cimino M, Wekselman F, Cobigo Y, Gorno-Tempini ML, et al. Detection of Alzheimer Neuropathology in Alzheimer and Non-Alzheimer Clinical Syndromes With Blood-Based Biomarkers. JAMA neurology. 2025. doi:10.1001/jamaneurol.2024.5017. PMID: 39928343.
BibTeX
@article{vandevrede2025-39928343,
author = {VandeVrede, L. and Cho, H. and Sanderson-Cimino, M. and Wekselman, F. and Cobigo, Y. and Gorno-Tempini, M. L. and Heuer, H. W. and Kramer, J. H. and others},
title = {{Detection of Alzheimer Neuropathology in Alzheimer and Non-Alzheimer Clinical Syndromes With Blood-Based Biomarkers}},
journal = {JAMA neurology},
year = {2025},
doi = {10.1001/jamaneurol.2024.5017},
pmid = {39928343},
url = {https://doi.org/10.1001/jamaneurol.2024.5017}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Importance Blood-based biomarkers for Alzheimer disease (AD) are clinically available, but their value is not well understood in syndromes typically associated with frontotemporal lobar degeneration syndromes (FTLD).
- Results A total of 349 individuals (191 [55%] male; mean [SD] age at death, 72 [11] years) were included.
Why it matters
This clinicopathological study measured three blood biomarkers (p-tau217, NfL, and GFAP) in 349 autopsied individuals, including people with syndromes usually linked to frontotemporal lobar degeneration. It examined whether these blood tests can detect Alzheimer's disease pathology in people whose clinical syndrome is not typical Alzheimer's, but the available summary does not report how well the biomarkers performed.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants125
- Evidence strengthLow
How this study scored 59/100
Published in a leading specialty journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (JAMA neurology) |
| Journal's citation record | 2 / 4 | JAMA Neurology: journal h-index 235 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 125 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 57 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 19.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 5 / 6 | Cited 36.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 7 other studies in this library |
| Still being cited | 3 / 4 | Cited 57 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Adam L. Boxer: h-index 98 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of California, San Francisco: institution h-index 1,915 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 39928343) |
| Free to read | 2 / 2 | Free to read |
| Total | 59 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1001/jamaneurol.2024.5017
- PubMed: 39928343
- Original source →
- Free full text: PubMed Central →
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 24.
Later studies that cite this one
7 studies in the alzhub library list this one in their references.
Related studies in Biomarkers from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.